A microRNA contribution to aberrant Ras activation in gastric cancer
- PMID: 21416062
- PMCID: PMC3056566
A microRNA contribution to aberrant Ras activation in gastric cancer
Abstract
Oncogenic Ras mutations are rare in gastric cancer, indicating that other mechanisms may be responsible for aberrant Ras activation in this type of cancer. Ezrin is critical to Ras activation by remodeling cortical actin cy-toskeleton. In this study, we aimed to illustrate the relevance and regulation of ezrin in gastric cancer. Ezrin was upregulated in gastric cancer cells. Ezrin siRNA inhibited Ras activation, cell growth and cell migration. Ezrin overex-pression was correlated with a poor outcome of gastric cancer patients (n=150, p<0.01). Cox regression analysis revealed a significant value of ezrin expression in prognosis prediction of gastric cancer (relative risk: 2.37, 95% confidence interval: 1.24-4.56, p<0.01). MiR-204, which was predicted to target ezrin, was downregulated in gastric cancer cells and gastric carcinomas (n=22, p<0.01). MiR-204 inhibited ezrin expression, Ras activation, cell growth and cell migration. Importantly, miR-204 suppressed the expression of luciferase controlled by wild-type but not mutated ezrin 3'-UTR. In conclusion, ezrin is important to Ras activation in gastric cancer. Its upregulation is an independent prognosis prediction factor for gastric cancer. By contributing to ezrin upregulation, miR-204 downregulation represents a novel mechanism for aberrant Ras activation in gastric carcinogenesis.
Keywords: Ezrin; Ras; gastric cancer; miR-204.
Figures
Similar articles
-
Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin.Am J Pathol. 2012 Jun;180(6):2440-51. doi: 10.1016/j.ajpath.2012.02.023. Epub 2012 Apr 21. Am J Pathol. 2012. PMID: 22525461
-
MicroRNA-409-5p is upregulated in breast cancer and its downregulation inhibits cancer development through downstream target of RSU1.Tumour Biol. 2017 May;39(5):1010428317701647. doi: 10.1177/1010428317701647. Tumour Biol. 2017. PMID: 28459205
-
MiR-105 inhibits gastric cancer cells metastasis, epithelial-mesenchymal transition by targeting SOX9.Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6160-6169. doi: 10.26355/eurrev_201907_18429. Eur Rev Med Pharmacol Sci. 2019. PMID: 31364116
-
microRNA-96 acts as a tumor suppressor gene in human osteosarcoma via target regulation of EZRIN.Life Sci. 2018 Jun 15;203:1-11. doi: 10.1016/j.lfs.2018.04.012. Epub 2018 Apr 12. Life Sci. 2018. PMID: 29656060
-
MicroRNA-150 upregulation reduces osteosarcoma cell invasion and metastasis by downregulating Ezrin.Oncol Lett. 2016 Nov;12(5):3457-3462. doi: 10.3892/ol.2016.5046. Epub 2016 Aug 25. Oncol Lett. 2016. PMID: 27900020 Free PMC article.
Cited by
-
The dual regulatory role of miR-204 in cancer.Tumour Biol. 2016 Sep;37(9):11667-11677. doi: 10.1007/s13277-016-5144-5. Epub 2016 Jul 20. Tumour Biol. 2016. PMID: 27438705 Free PMC article. Review.
-
miR-486-3p, miR-139-5p, and miR-21 as Biomarkers for the Detection of Oral Tongue Squamous Cell Carcinoma.Biomark Cancer. 2017 Nov 7;9:1179299X1700900001. doi: 10.1177/1179299X1700900001. eCollection 2017. Biomark Cancer. 2017. PMID: 35237086 Free PMC article.
-
Nuclear Drosha enhances cell invasion via an EGFR-ERK1/2-MMP7 signaling pathway induced by dysregulated miRNA-622/197 and their targets LAMC2 and CD82 in gastric cancer.Cell Death Dis. 2017 Mar 2;8(3):e2642. doi: 10.1038/cddis.2017.5. Cell Death Dis. 2017. PMID: 28252644 Free PMC article.
-
LPS‑induced downregulation of microRNA‑204/211 upregulates and stabilizes Angiopoietin‑1 mRNA in EA.hy926 endothelial cells.Mol Med Rep. 2017 Nov;16(5):6081-6087. doi: 10.3892/mmr.2017.7400. Epub 2017 Aug 30. Mol Med Rep. 2017. PMID: 28901393 Free PMC article.
-
Association of Ezrin expression with the progression and prognosis of gastrointestinal cancer: a meta-analysis.Oncotarget. 2017 Oct 4;8(54):93186-93195. doi: 10.18632/oncotarget.21473. eCollection 2017 Nov 3. Oncotarget. 2017. PMID: 29190988 Free PMC article.
References
-
- Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424–430. - PubMed
-
- Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295–308. - PubMed
-
- Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P. Merlin/ neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res. 2007;67:520–527. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources